Baird Financial Group, Inc. Ligand Pharmaceuticals Inc Transaction History

Baird Financial Group, Inc.

$50 Billion
Q1 2025

A detailed history of Baird Financial Group, Inc. transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Baird Financial Group, Inc. holds 11,637 shares of LGND stock, worth $1.31 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,637

Previous 77,207 84.93%

Holding current value

$1.31 Million

Previous $8.27 Million 85.22%

% of portfolio

0.0%

Previous 0.02%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$105.14 - $122.23 $6.89 Million - $8.01 Million	-65,570 Reduced 84.93%	11,637 $1.22 Million
Q4 2024 Feb 14, 2025	BUY	$99.95 - $129.9 $613,992 - $797,975	6,143 Added 8.64%	77,207 $8.27 Million
Q3 2024 Nov 13, 2024	BUY	$82.7 - $110.11 $1.18 Million - $1.57 Million	14,287 Added 25.16%	71,064 $7.12 Million
Q2 2024 Aug 13, 2024	BUY	$68.53 - $87.91 $306,123 - $392,693	4,467 Added 8.54%	56,777 $4.78 Million
Q1 2024 May 14, 2024	BUY	$68.64 - $89.2 $880,994 - $1.14 Million	12,835 Added 32.51%	52,310 $3.82 Million
Q4 2023 Feb 14, 2024	SELL	$49.57 - $72.63 $72,818 - $106,693	-1,469 Reduced 3.59%	39,475 $2.82 Million
Q3 2023 Nov 13, 2023	SELL	$58.86 - $72.67 $142,558 - $176,006	-2,422 Reduced 5.59%	40,944 $2.45 Million
Q2 2023 Aug 11, 2023	BUY	$69.53 - $79.33 $2.44 Million - $2.79 Million	35,121 Added 425.97%	43,366 $3.13 Million
Q1 2023 May 15, 2023	BUY	$65.67 - $77.08 $307,598 - $361,042	4,684 Added 131.54%	8,245 $606,000
Q3 2022 Nov 14, 2022	BUY	$0.01 - $107.56 $0 - $6,991	65 Added 1.76%	3,763 $324,000
Q2 2022 Aug 08, 2022	BUY	$74.52 - $117.06 $16,319 - $25,636	219 Added 6.29%	3,698 $330,000
Q1 2022 May 13, 2022	SELL	$94.99 - $151.56 $4,559 - $7,274	-48 Reduced 1.36%	3,479 $391,000
Q4 2021 Feb 09, 2022	SELL	$127.69 - $165.85 $152,334 - $197,859	-1,193 Reduced 25.28%	3,527 $545,000
Q3 2021 Nov 12, 2021	BUY	$102.33 - $144.73 $94,552 - $133,730	924 Added 24.34%	4,720 $658,000
Q2 2021 Aug 11, 2021	SELL	$113.03 - $155.64 $97,092 - $133,694	-859 Reduced 18.45%	3,796 $498,000
Q1 2021 May 13, 2021	SELL	$99.52 - $215.83 $14,828 - $32,158	-149 Reduced 3.1%	4,655 $710,000
Q4 2020 Feb 11, 2021	SELL	$80.55 - $106.05 $10,068 - $13,256	-125 Reduced 2.54%	4,804 $478,000
Q3 2020 Nov 12, 2020	SELL	$89.56 - $126.72 $129,682 - $183,490	-1,448 Reduced 22.71%	4,929 $470,000
Q2 2020 Oct 22, 2020	SELL	$68.28 - $123.65 $82,482 - $149,369	-1,208 Reduced 15.93%	6,377 $713,000
Q2 2020 Aug 14, 2020	BUY	$68.28 - $123.65 $137,106 - $248,289	2,008 Added 36.01%	7,585 $803,000
Q1 2020 May 14, 2020	SELL	$63.37 - $107.88 $102,659 - $174,765	-1,620 Reduced 22.51%	5,577 $406,000
Q4 2019 Feb 14, 2020	SELL	$96.94 - $113.59 $2.27 Million - $2.66 Million	-23,440 Reduced 76.51%	7,197 $751,000
Q3 2019 Nov 14, 2019	BUY	$86.25 - $120.16 $54,596 - $76,061	633 Added 2.11%	30,637 $3.05 Million
Q2 2019 Aug 14, 2019	BUY	$107.38 - $129.34 $3.22 Million - $3.88 Million	30,004 New	30,004 $3.43 Million

Others Institutions Holding LGND

# of Institutions

280

Shares Held

19M

Call Options Held

9.5K

Put Options Held

8.1K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.9B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baird Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Baird Financial Group, Inc. with notifications on news.

Account

Baird Financial Group, Inc. Ligand Pharmaceuticals Inc Transaction History